FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumors

Share This Post

May 2022: FDA approves clinical trial application of specific CAR-NK therapy FT536 in the treatment of solid tumours in a CAR-NK clinical trial. The FDA approved an Investigational New Drug Application in January 2022 for the CAR-NK treatment FT536 to treat individuals with relapsed or resistant solid malignancies. In this trial, patients with advanced non-small cell lung cancer, colorectal cancer, head and neck cancer, gastric cancer, breast cancer, ovarian cancer, and pancreatic cancer will receive FT536 as a monotherapy or in combination with a monoclonal antibody. FT536 (Fate Therapeutics) is an allogeneic, multiple-engineered natural killer (NK) cell treatment produced from induced pluripotent stem cells.

This is a genetically engineered NK cell treatment that expresses a CAR that targets the alpha-3 domains of MICA and MICB, two proteins involved in the major histocompatibility complex class I. Both are stress proteins that are extensively produced in many solid tumours and can overcome shedding to restore tumour immunity mediated by NK and T cells. Overall, FT536 contains four functional modifications: a proprietary CAR targeting MICA and MICB’s 3 domain; a novel high-affinity 158V, non-cleavable CD16 (hnCD16) Fc receptor that enhances ADCC; promotes enhanced NK cells Active IL-15 receptor fusion (IL-15RF); and abrogation of CD38 expression, thereby enhancing NK cell metabolic fitness, persistence, and antitumor function.

We expect that FT536 therapy can obtain positive data as soon as possible in clinical trials of solid tumors, and it will be launched as soon as possible to benefit patients.

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/